Rising Star: Risk and benefit of treatment in IBD: From real-world data to robust real-world evidence
In this medfyle
Randomized controlled trials cannot adequately assess rare events in chronic long-term conditions such as inflammatory bowel disease. Real-world evidence can increase confidence and support treatment decisions by examining specific populations, new treatment comparisons, new outcomes, or long-term follow-up in real-life settings.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
This is a summary of an oral session given at the UEG Week 2022 and presented by:
Prof. Julien Kirchgesner
Saint-Antoine Hospital
Pierre Louis Institute of Epidemiology and Public Health
Sorbonne Université
Paris, France
The content is produced by Infomedica. The presenting authors of the original session had no part in the creation of this conference summary.
